Induced Pluripotent Stem Cells 10 Years Later

DOI Web Site 18 Citations 167 References
  • Yoshinori Yoshida
    From the Center for iPS Cell Research and Application, Kyoto University, Japan (Y.Y., S.Y.); and Gladstone Institute of Cardiovascular Disease, Gladstone Institutes, San Francisco, CA (S.Y.).
  • Shinya Yamanaka
    From the Center for iPS Cell Research and Application, Kyoto University, Japan (Y.Y., S.Y.); and Gladstone Institute of Cardiovascular Disease, Gladstone Institutes, San Francisco, CA (S.Y.).

Bibliographic Information

Other Title
  • For Cardiac Applications

Description

<jats:p>Induced pluripotent stem cells (iPSCs) are reprogrammed cells that have features similar to embryonic stem cells, such as the capacity of self-renewal and differentiation into many types of cells, including cardiac myocytes. Although initially the reprogramming efficiency was low, several improvements in reprogramming methods have achieved robust and efficient generation of iPSCs without genomic insertion of transgenes. iPSCs display clonal variations in epigenetic and genomic profiles and cellular behavior in differentiation. iPSC-derived cardiac myocytes (iPSC cardiac myocytes) recapitulate phenotypic differences caused by genetic variations, making them attractive human disease models, and are useful for drug discovery and toxicology testing. In addition, iPSC cardiac myocytes can help with patient stratification in regard to drug responsiveness. Furthermore, they can be used as source cells for cardiac regeneration in animal models. Here, we review recent progress in iPSC technology and its applications to cardiac diseases.</jats:p>

Journal

  • Circulation Research

    Circulation Research 120 (12), 1958-1968, 2017-06-09

    Ovid Technologies (Wolters Kluwer Health)

Citations (18)*help

See more

References(167)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top